ENTO ENTERO THERAPEUTICS INC Management Changes 8-K Filing 2025 - Management Changes Entero Therapeutics Inc reported on March 6, 2025, that it received a notice from Nasdaq about not meeting the minimum bid price requirement for its stock, and it appointed Anna Skowron as CFO and Richard Paolone as CEO, with respective monthly compensations of $8,333 and $12,500.Get access to all SEC 8-K filings of the ENTERO THERAPEUTICS INC